[Skip to Content]
[Skip to Content Landing]
Citations 0
Letters
October 20, 1999

Cost-effectiveness of Methods to Enhance Sensitivity of Papanicolaou Testing—Reply

Author Affiliations
 

Margaret A.WinkerMD, Deputy EditorIndividualAuthorPhil B.FontanarosaMD, Interim CoeditorIndividualAuthor

JAMA. 1999;282(15):1419-1420. doi:10-1001/pubs.JAMA-ISSN-0098-7484-282-15-jac90009

In Reply: As Dr Leidy and colleagues and Dr Sedlacek state, we believe that quality-adjusted life-years constitute the preferred measure of outcomes. We reported outcomes in life-years to preserve comparability to the major published cost-effectiveness analyses of cervical cancer screening. Furthermore, reliable estimates of the effects of the technologies on quality of life are unavailable. A clinical trial comparing the technologies that measured changes in quality of life and life expectancy might be the best way to assess cost-effectiveness. It would be surprising, however, if such a trial produced findings substantially different from those we reported. In preliminary analyses, we calculated the effects of the new technologies on quality-adjusted life-years, using a wide range of values for quality of life. The results were similar to those reported in the article.

First Page Preview View Large
First page PDF preview
First page PDF preview
×